Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study on safety and tolerability of repeated mobilization of osteo-medullary derived cells in ALS
2005-003248-75Phase 2Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Sep 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lenograstim in amyotrophic lateral sclerosis (ALS), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Safety and tolerability of repeated mobilization procedures. Started Sep 2005; status: active.
02
Drugs
lenograstim
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2005-003248-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003248-75.